BioCryst Pharmaceuticals | BCRX - Current Assets


BioCryst Pharmaceuticals reported $373.62M in Current Assets for its fiscal quarter ending in March of 2026.





Current Assets Change Date
Alnylam Pharmaceuticals USD 4.22B 168.65M Mar/2026
BioCryst Pharmaceuticals USD 373.62M 30.72M Mar/2026
Chugai Pharma JPY 1.54T 201.32B Mar/2026
Daiichi Sankyo JPY 2.1T 218.5B Dec/2025
DBV Technologies USD 212.94M 124.06M Dec/2025
Enanta Pharmaceuticals USD 198.68M 5.65M Dec/2025
Gilead Sciences USD 18.64B 1.25B Mar/2026
GlaxoSmithKline GBP 17.76B 251M Mar/2026
Glaxosmithkline GBP 23.59B 390.44M Dec/2025
Incyte USD 5.48B 460.36M Mar/2026
Ionis Pharmaceuticals USD 2.94B 52M Mar/2026
Karyopharm Therapeutics USD 103.15M 13.4M Dec/2025
Neurocrine Biosciences USD 2.44B 86.6M Mar/2026
Novavax USD 850.82M 127.46M Mar/2026
PTC Therapeutics USD 2.25B 19.94M Mar/2026
Regeneron Pharmaceuticals USD 18.21B 187.3M Mar/2026
Roche Holding CHF 38.73B 3.03B Dec/2025
Sarepta Therapeutics USD 2.31B 228.06M Mar/2026
Ultragenyx Pharmaceutical USD 657M 294M Mar/2026
Vertex Pharmaceuticals USD 11.73B 529.3M Mar/2026